The bulls can show them around the place.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, today announced the appointment of David-Alexandre "DA" Gros, M.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.
Alynlam Pharmaceuticals (ALNY) shares declined despite earnings and revenue numbers that topped analysts' expectations.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2015, and highlighted recent progress in advancing its pipeline.